Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Curr Probl Cardiol ; 49(1 Pt C): 102089, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37774898

ABSTRACT

ST elevation myocardial infarction (STEMI) is a leading cause of cardiogenic shock (CS) and carries substantial mortality. Cardiac power output (CPO) is the strongest predictor of clinical outcome in CS, and worse outcomes result from concomitant right and left ventricular failure. Right ventricular performance is calculated using right sided CPO. Our aim was to measure the right sided CPO and compute their ratio to predict in-hospital mortality in STEMI patients with cardiogenic shock. This was a retrospective observational study of consecutive STEMI patients with CS that developed within the first 24hours of admission requiring left and right cardiac catheterization at a large tertiary care center from January 2014-December 2018. One hundred sixty-four patients identified with STEMI; 46% (75) excluded due to incomplete data. 88 remaining patients, 52.8% (47) developed CS. 98.9% within 24 hours. Mean left & right CPO 0.62 (SD 0.3) and 0.22 (SD 0.13), PAPi score 1.81. Logistic regression analysis indicated odds ratio of in-hospital mortality lower for low left CPO, high right CPO and low ratio of left to right CPO (95% CI; 0.69, 0.34, 1.20; 1.38, 0.87, 2.20; 0.52, 0.28, 1.00 respectively). This is the first study to assess right sided CPO and ratio of right and left side CPO and mortality. Our study indicates that there is trend towards higher in-hospital mortality in patients with high right sided CPO and lower ratio of left to right CPO. The exploratory results of this study need to be confirmed in a larger population.


Subject(s)
Percutaneous Coronary Intervention , ST Elevation Myocardial Infarction , Humans , Shock, Cardiogenic/diagnosis , Shock, Cardiogenic/etiology , Shock, Cardiogenic/therapy , ST Elevation Myocardial Infarction/complications , ST Elevation Myocardial Infarction/diagnosis , Retrospective Studies , Percutaneous Coronary Intervention/adverse effects , Treatment Outcome , Observational Studies as Topic
2.
Breast J ; 27(4): 384-386, 2021 04.
Article in English | MEDLINE | ID: mdl-33527538

ABSTRACT

Malignancy has historically prohibited solid organ transplant; however, patients with effectively treated, favorable-risk cancers should not necessarily be eliminated as transplant candidates. These cases require careful review by a multidisciplinary team. Here, we report the case of a woman with end-stage heart failure undergoing heart transplant evaluation during the COVID pandemic who was found to have early-stage, hormone receptor-positive breast cancer. Given her favorable cancer-related prognosis, a multidisciplinary committee recommended lumpectomy, accelerated partial breast irradiation, and adjuvant aromatase inhibitor therapy for definitive treatment to allow for consideration of orthotopic heart transplant.


Subject(s)
Breast Neoplasms/complications , COVID-19/complications , Cardiomyopathies/complications , Heart Failure/complications , Breast Neoplasms/surgery , Female , Heart Transplantation , Humans , Middle Aged , Pandemics
3.
J Am Heart Assoc ; 6(2)2017 02 10.
Article in English | MEDLINE | ID: mdl-28188253

ABSTRACT

BACKGROUND: This study aimed to demonstrate the feasibility of measuring frailty in patients with cardiac implantable electrical devices while validating the physiologic significance of device-detected physical activity by evaluating its association with frailty and mobility. METHODS AND RESULTS: Outpatients with cardiac implantable electrical devices compatible with physical activity analysis with at least 7 days of data were eligible. Office testing included frailty status (Study of Osteoporotic Fractures instrument), gait speed (m/s), mobility according to the Timed Up and Go (TUG) test (seconds), and daily physical activity (h/d) as measured by cardiac implantable electrical device. Among 219 patients, Study of Osteoporotic Fractures testing found 39.7% to be robust, 47.5% prefrail, and 12.8% frail. The mean gait speed for the cohort was 0.8±0.3 m/s, mean TUG time was 10.9±4.4 seconds, and mean activity was 2.8±1.9 h/d. Frail patients were markedly more likely to have gait speeds <0.8 m/s (OR 6.25, 95% CI 1.79-33.3). In unadjusted analyses each 1-hour increase in mean daily activity was associated with a 46% reduction of frail phenotype (OR 0.54, 95% CI 0.40-0.74) versus robust and with a 27% reduction in the odds of having the prefrail phenotype (OR 0.73, 95% CI 0.62-0.86). After adjustment this association per hour of activity persisted, with an adjusted OR for frailty of 0.71 (95% CI 0.51-0.99) and adjusted OR for prefrailty of 0.81 (95% CI 0.67-0.99). CONCLUSIONS: Frailty and mobility limitation are common among cardiac implantable electrical device patients and are correlated to device-detected physical activity.


Subject(s)
Arrhythmias, Cardiac/rehabilitation , Defibrillators, Implantable , Exercise/physiology , Frailty/rehabilitation , Geriatric Assessment/methods , Pacemaker, Artificial , Walking/physiology , Aged , Arrhythmias, Cardiac/epidemiology , Arrhythmias, Cardiac/therapy , Cross-Sectional Studies , Female , Follow-Up Studies , Frail Elderly , Frailty/epidemiology , Humans , Incidence , Male , Massachusetts/epidemiology , Mobility Limitation , Outpatients , Risk Factors , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...